Inhibitory Receptor Paired Ig-like Receptor B Is Exploited by Staphylococcus aureus for Virulence

Masafumi Nakayama, Kenji Kurokawa, Kyohei Nakamura, Bok Luel Lee, Kazuhisa Sekimizu, Hiromi Kubagawa, Keiichi Hiramatsu, Hideo Yagita, Ko Okumura, Toshiyuki Takai, David M. Underhill, Alan Aderem and Kouetsu Ogasawara
J Immunol December 15, 2012, 189 (12) 5903-5911; DOI: https://doi.org/10.4049/jimmunol.1201940

Abstract

The innate immune system has developed to acquire a wide variety of pattern-recognition receptors (PRRs) to identify potential pathogens, whereas pathogens have also developed to escape host innate immune responses. ITIM-bearing receptors are attractive targets for pathogens to attenuate immune responses against them; however, the in vivo role of the inhibitory PRRs in host–bacteria interactions remains unknown. We demonstrate in this article that Staphylococcus aureus, a major Gram-positive bacteria, exploits inhibitory PRR paired Ig-like receptor (PIR)-B on macrophages to suppress ERK1/2 and inflammasome activation, and subsequent IL-6 and IL-1β secretion. Consequently, Pirb−/− mice infected with S. aureus showed enhanced inflammation and more effective bacterial clearance, resulting in resistance to the sepsis. Screening of S. aureus mutants identified lipoteichoic acid (LTA) as an essential bacterial cell wall component required for binding to PIR-B and modulating inflammatory responses. In vivo, however, an LTA-deficient S. aureus mutant was highly virulent and poorly recognized by macrophages in both wild-type and Pirb−/− mice, demonstrating that LTA recognition by PRRs other than PIR-B mediates effective bacterial elimination. These results provide direct evidence that bacteria exploit the inhibitory receptor for virulence, and host immune system counterbalances the infection.

Introduction

Staphylococcus aureus, a Gram-positive bacteria, is a major source of mortality in medical facilities (1, 2). Although S. aureus often causes skin infections, it can also spread to the bloodstream and lead to life-threatening sepsis. Because S. aureus infections cause relatively mild inflammation compared with Gram-negative infections (3, 4), anti-inflammatory therapies do not improve survival, and can have a detrimental effect on Gram-positive sepsis outcomes (5). Thus, Gram-positive infections are more difficult to cure than those with Gram-negative bacteria (2, 6).

Among pattern-recognition receptors (PRRs), TLR2 plays a crucial role in sensing S. aureus lipoproteins and inducing production of inflammatory cytokines such as IL-6 and TNF-α (7). Further, intracellular NLRP3 inflammasomes are activated by S. aureus α-toxins and peptidoglycan to secret IL-1β (8, 9). In addition to these sensors, several other PRRs directly bind whole S. aureus bacteria and contribute to their elimination in vivo. For example, the class B scavenger receptor CD36, class A scavenger receptor (SR-A), and mannose-binding lectin (MBL) recognize lipoteichoic acid (LTA) and facilitate phagocytic clearance of S. aureus (10). Recently, human MBL has been shown to bind S. aureus wall teichoic acid (WTA) to activate complement pathway (11).

To survive in the host, S. aureus evades host immune responses using several mechanisms, including resistance to specific antimicrobial peptides, neutralization of reactive oxygen species, inactivation of complement, inhibition of neutrophil migration, and evasion of phagocytosis (12, 13). Given that S. aureus–induced sepsis produces lower levels of inflammatory cytokines than does Gram-negative sepsis (3, 4), S. aureus must have additional strategies to dampen host inflammatory responses.

We have recently identified murine paired Ig-like receptor (PIR)-B (14, 15) as a novel macrophage receptor for S. aureus (16). PIR-B has four ITIMs in the cytoplasmic domain and inhibits activating signals by surface receptors (14, 15). PIR-B transcript is detected in spleen and bone marrow (14), and the cell surface expression is observed on various hematopoietic cells including macrophages, monocytes, granulocytes, B cells, and dendritic cells (15). Given that PIR-B suppresses TLR-mediated proinflammatory cytokine production in vitro (16), we hypothesized that S. aureus specifically targets the inhibitory PIR-B to dampen inflammatory responses. Likewise, Moraxella catarrhalis and Neisseria meningitidis bind ITIM-bearing carcinoembryonic Ag-related cell adhesion molecule 1 to suppress TLR2-mediated inflammatory responses in human pulmonary epithelial cells (17). Group B Streptococcus also exploits ITIM-bearing Sia-recognizing Ig superfamily lectin-5 or -9 to suppress phagocytosis and oxidative burst in human leukocytes (18). These findings support the current hypothesis that pathogens may have evolved to target inhibitory receptors to survive in the host (19, 20). However, it remains unknown whether inhibitory PRRs are indeed beneficial for bacterial survival in vivo. Alternatively, these inhibitory PRRs may fine-tune inflammatory responses to perfectly balance bacterial clearance, whereas limiting tissue damage caused by excessive inflammation.

In this study, we sought to determine the in vivo role of PIR-B in host defense against S. aureus infection. Moreover, by screening various S. aureus mutant strains with defects in cell-wall components, we revealed the machinery underlying the interaction between PIR-B and this bacterium.

Materials and Methods

Mice

Six-week-old female C57BL/6 mice were obtained from Charles River Japan (Yokohama, Japan). Pirb−/− mice (129/SvJ/C57BL/6 background) (21) were backcrossed for at least 10 generations with C57BL/6 mice. β2-microglobulin (β2m)–deficient mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained under specific pathogen-free conditions and used according to the guidelines of the Institutional Animal Care and Use Committee established at Juntendo University and Tohoku University.

Bacterial mutant construction

In S. aureus T363 strain, the lgt gene, which encodes preprolipoprotein diacylglycerol transferase, has been disrupted in RN4220 cells by replacement with a Phleo resistance gene by double-crossover recombination as described previously (22) but using the pKOR1 plasmid to select for a recombinant mutant in S. aureus (23). In brief, a DNA fragment upstream or downstream of the lgt gene was amplified using primers of lgt-Pa (5′-CTGAGGTACCAAGACCGGGCTTAGAGATGG-3′) and lgt-Pb (5′-GTCTATTGGATCCTAAGTTAAATGCCACAGGA-3′) or lgt-P3 (5′-GTTCAGCAATCGCTTCCATGGCCAACAAAA-3′) and lgt-P4 (5′-ACCGAATTCGCATGTCCAATTTCCACTT-3′), respectively. The Phleo resistance gene was amplified with Phleo-P2 (5′-GGATCCAATAGACCAGTTGCA-3′) and Phleo-P3 (5′-CGATTGCTGAACAGATTAATAATAGA-3′), containing sequences complementary to lgt-Pb and lgt-P3, respectively. Next, three amplified fragments were connected by joining PCR, and the resultant fragment was inserted at the KpnI and EcoRI sites of pKOR1 plasmid. The resultant plasmid was introduced into RN4220 cells, and double-crossover homologous recombinants were selected and named T363. Deletion of the chromosomal lgt gene was confirmed by PCR. S. aureus and Escherichia coli strains were grown in Luria–Bertani (LB) medium (1% tryptone, 0.5% yeast extract, and 1% NaCl) containing, where appropriate, 100 μg/ml ampicillin, 12.5 μg/ml chloramphenicol, 20 μg/ml phleomycin, or 0.1 μg/ml anhydrotetracycline at the appropriate temperature.

Bacterial culture and fluorescent labeling

The strains of bacteria and plasmids used in this study are listed in Table I. The strains deficient in the expression of genes responsible for the synthesis of cell-wall components were derivates of the wild-type (WT) strain RN4220 (24). RN4220, T363, and M0587 (25) were cultured in LB medium at 37°C. T174 (26), M0674/pM101 (22), and M0674/pM101-ltaS (22) were cultured in LB medium supplemented with the appropriate antibiotics at 30°C. M0793 (26), M0875 (26), NI-1 (27), NI43 (28), and JT1304 (29) were cultured in LB medium supplemented with appropriate antibiotics at 37°C. After overnight growth, all S. aureus strains were diluted 1:50 (v/v) and were grown for 5 h. Then S. aureus were harvested and washed with PBS. The concentration of bacterial CFU was calculated as: OD600 = 1, CFU = 4.5 × 108/ml. Bacteria were labeled with TAMRA (Invitrogen, Carlsbad, CA; 50 μg/ml in PBS) at 37°C for 30 min and then washed with 5% FCS in PBS five times.

View this table:
Table I. S. aureus strains and plasmids used in this study

Measurement of cells recognizing S. aureus in vivo

Mice (n = 3/group) were i.v. injected with TAMRA-labeled S. aureus. One hour later, mice were sacrificed and splenocytes were prepared with collagenase digestion as described previously (30). TAMRA fluorescence intensity in CD11b+ F4/80+, CD8+ CD11c+, CD8− CD11c+, CD3+, and B220+ cells were analyzed by flow cytometry using FITC–anti-CD11b, allophycocyanin–anti-F4/80, allophycocyanin–anti-CD8α, FITC–anti-CD11c, FITC–anti-CD3, and allophycocyanin-B220 mAbs (BioLegend, San Diego, CA).

Bacterial infection in vivo

Female WT and Pirb−/− mice were i.v. infected with the indicated dose of bacteria and survival was monitored for 15 d. Mice were monitored daily and were sacrificed when moribund to avoid pain and suffering. For measurement of cytokine and bacterial CFU in blood, mice were i.v. infected with the indicated CFU of bacteria and sacrificed on day 1 or 2 postinfection. Blood was diluted 10-fold step with PBS containing 0.2% Triton X-100. Bacterial CFU were determined by plating dilutions on LB agar plates and culturing for 24 h. Serum was prepared from blood, and the amounts of IL-6 and IL-1β in serum were measured by ELISA.

Measurement of cytokines

The amount of IL-6 and IL-1β in culture supernatants and mouse serum were measured by the ELISA Kit (R&D Systems, Minneapolis, MN) according to the manufacturers’ instructions.

Immunoblot

Bone marrow–derived macrophages (BMDMs) infected with S. aureus for the indicated periods were solubilized in RIPA buffer (1% Nonidet P-40, 50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.5% deoxycholate, and 10% SDS, 1 mM sodium vanadate, 1 mM sodium fluoride, 1 mM PMSF, aprotinin [1 μg/ml], and leupeptin [1 μg/ml]). Cell lysates were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA), followed by detection with Abs against MAPK family members (Cell Signaling, Boston, MA) or IκB-α (Santa Cruz, CA). For immunoprecipitation of PIR-B, cell lysates were precleared with protein G (GE Healthcare Piscataway, NJ), then incubated with 6C1 (31), followed by protein G. Phosphorylation levels of PIR-B were analyzed using 4G10 (Millipore, Bedford, MA) and anti-PIR Abs (R&D Systems). For analysis of IL-1β and caspase-1 processing, immunoblots were performed as described previously (9) with minor modifications. In brief, WT and Pirb−/− BMDMs were seeded on six-well plates and cultured overnight. After replacing the media with serum-free media containing M-CSF, cells were cultured with S. aureus RN4220 (10 multiplicity of infection [moi]) for the indicated periods of time. Culture supernatants and total cell lysates were pooled and then clarified by centrifugation. Proteins were precipitated with Strataclean resin (Stratagene, La Jolla, CA) and detected by immunoblot with anti–IL-1β Ab (R&D systems), anti–caspase-1 Ab (Santa Cruz), and β-actin mAb (BioLegend).

Cell lines

HEK293 cells and NIH3T3 cells (American Type Culture Collection, Rockville, MD) were maintained in complete DMEM supplemented with 10% FBS and 2 mM glutamine. The coding region of PIR-B was subcloned into pEF6V5-TOPO (Invitrogen). The coding regions for FcγRIII, FcRγ, CD36, and SR-A were amplified from C57BL/6 BMDM cDNAs, then inserted into pEF6V5-TOPO or pMXs-IRES-Puro (provided by Toshio Kitamura, University of Tokyo). PIR-B/NIH3T3 cells, and mutant form (PSYDR-G119E, P210A) of PIR-B/NIH3T3 cells, FcRγ/HEK293 cells, CD36/NIH3T3 cells, and SR-A/NIH3T3 cells were generated by retroviral transduction as described previously (16). PIR-B/pEF6V5-TOPO or FcγRIII/pEF6V5-TOPO was transfected into HEK293 cells or FcRγ/HEK293 cells, respectively, using Lipofectamine 2000 (Invitrogen).

Phagocytosis assay by trypan blue quenching system

Parental HEK293 cells and 293 cells stably expressing PIR-B or FcγRIII plus Fcγ common chain (105 cells/well) were plated onto a poly-l-lysine (Sigma-Aldrich, St. Louis, MO)–precoated 24-well plate 1 d before the phagocytosis assay. Cell lines were incubated with FITC-labeled S. aureus (10 moi). For FcR-mediated phagocytosis, FITC-labeled S. aureus were opsonized with anti-FITC mAb (mIgG1/k; BioLegend). FITC fluorescence intensity was quenched by trypan blue as described previously (32). In brief, the fluorescence of extracellular bacteria was quenched by replacing the medium with 0.2% trypan blue in PBS (pH 5.5); then cells were analyzed on a FACSCalibur (BD Biosciences).

Confocal microscopy

HEK293 cells cocultured with FITC-labeled bacteria were permeabilized with 0.1% Triton X-100 and stained with AF594-phalloidin (0.15 μM; Invitrogen). After fixation with 4% paraformaldehyde, cells were analyzed on a Carl Zeiss confocal laser-scanning microscope LSM510 equipped with ×40 objective lens, as described previously (33).

Measurement of cells recognizing S. aureus in vitro

Binding of S. aureus to PIR-B was analyzed as described previously (16). In brief, NIH3T3 cells, PIR-B/NIH3T3 cells, and mutant form (PSYDR-G119E, P210A) of PIR-B/NIH3T3 cells, CD36/NIH3T3 cells, and SR-A/NIH3T3 cells were incubated with the indicated dose of the fluorescently labeled S. aureus for 30 min at 37°C. After incubation with S. aureus, cells were washed with PBS twice, then harvested and analyzed with a FACSCanto II (BD Biosciences, San Jose, CA). For competitive inhibition assays, cells were pretreated with the indicated dose of LTA (InvivoGen, San Diego, CA) for 30 min at 37°C.

Binding of LTA to PIR-B

NIH3T3 cells, PIR-B/NIH3T3 cells, and CD36/NIH3T3 cells were incubated with or without 50 μg/ml LTA (InvivoGen) for 30 min at 4°C. Cells were then stained with anti-LTA mAb (Hycult Biotech, Uden, The Netherlands), followed by biotinylated anti-mouse IgG3 mAb (BioLegend) and streptavidin-PE (BioLegend), and analyzed on a FACSCanto II (BD Biosciences).

Binding of S. aureus to BMDMs

WT, Pirb−/−, and β2m−/− mouse BMDMs (2 × 105 per well) were seeded on 24-well plate and cultured overnight. BMDMs were cultured with TAMRA-labeled S. aureus RN4220 (0.2, 1, or 5 moi) for 30 min at 4°C. Cells were then washed twice with PBS, harvested, and analyzed on a FACSCanto II (BD Biosciences).

Statistical analyses

Statistical significance was analyzed with two-tailed Student t test. Data for survival were analyzed according to the Kaplan–Meier method, and the univariate comparison of survival for control versus knockout group was tested using a log-rank test. The p values <0.05 were considered significantly different between comparing samples.

Results

S. aureus targets PIR-B for virulence in vivo

To address the in vivo role of PIR-B in the recognition of bacteria, we injected WT or Pirb−/− mice i.v. with fluorescently labeled live S. aureus. These bacteria are preferentially recognized by F4/80+ CD11b+ splenic macrophages in WT mice, and macrophage recognition of S. aureus was significantly impaired in Pirb−/− mice (Fig. 1A, 1B). These results suggest that splenic macrophages effectively access bacterial particles from the passing bloodstream, and that PIR-B plays a role in the direct recognition of S. aureus in vivo. To address whether PIR-B has the capacity to internalize bacteria, we performed an in vitro phagocytosis assay using a 293 cell reconstitution system (30). Expression of PIR-B on 293 cells enabled these cells to bind, but not internalize, bacteria (Supplemental Fig. 1), suggesting that PIR-B is a binding, but not a phagocytic, receptor for S. aureus.

FIGURE 1.
FIGURE 1.

S. aureus targets PIR-B on splenic macrophages in vivo. (A and B) WT and Pirb−/− mice (n = 3 per group) were i.v. injected with TAMRA-labeled live S. aureus (3 × 108 CFU per mouse). Recognition of bacteria by the indicated splenic cell subsets was analyzed 1 h later (A). Percentage of recognition was quantified, and data are represented as mean + SD in (B). *p < 0.05, two-tailed Student t test. Similar results were obtained in at least three independent experiments.

Although PIR-B negatively regulates inflammatory cytokine production in response to heat-killed S. aureus in vitro (16), it remains unknown whether the innate immune suppression by PIR-B is beneficial to the host or advantageous for pathogen survival. Thus, we next addressed this issue. Because S. aureus could spread to the bloodstream and lead to life-threatening sepsis (6), WT and Pirb−/− mice were i.v. infected with various doses of S. aureus, and their survival was monitored. When infected with 7 × 107 CFU S. aureus, all WT and Pirb−/− mice survived to day 15 (data not shown). Interestingly, on infection with 2 × 108 CFU of the bacteria, ∼30% of WT mice died, whereas all Pirb−/− mice survived to day 15 (Fig. 2A). A more distinct survival difference was observed when mice were infected with a high dose of bacteria (6 × 108 CFU); only 15% of WT mice survived, whereas >80% of Pirb−/− mice survived to day 15 (Fig. 2B). Although no significant difference was observed in blood bacterial number between WT and Pirb−/− mice at the early time point (5 h) postinfection, Pirb−/− mice showed effective clearance of bacteria in blood (Fig. 2C, 2D) and spleen (data not shown) on 1 d postinfection, consistent with the low mortality of Pirb−/− mice. In addition, IL-6 and IL-1β levels were increased in the serum of Pirb−/− mice infected with S. aureus (Fig. 2E). Thus, the loss of PIR-B resulted in enhanced proinflammatory cytokine production. On i.p. infection with 3 × 108 CFU S. aureus, all WT and Pirb−/− mice survived to day 15, but Pirb−/− mice showed the effective clearance of bacteria in peritoneal fluid on day 1 postinfection (data not shown). Taken together, the lack of negative feedback via PIR-B may accelerate bacterial clearance. These results suggest that PIR-B, an inhibitory PRR, is exploited by S. aureus for its survival and virulence.

FIGURE 2.
FIGURE 2.

Pirb−/− mice are less susceptible to S. aureus infection. (A and B) WT mice (n = 10 [A] or n = 12 [B]) and Pirb−/− mice (n = 10 [A] or n = 9 [B]) were i.v. infected with S. aureus (2 × 108 CFU [A] or 6 × 108 CFU [B] per mouse). Mouse survival was monitored for 15 d postinfection. (C and D) WT mice (n = 3 [C] or n = 6 [D]) and Pirb−/− mice (n = 3 [C] or n = 5 [D]) were i.v. infected with S. aureus (1 × 108 CFU [C] or 5 × 108 CFU [D] per mouse). Bacterial number in blood on 5 h, day 1, and day 2 postinfection was determined. Three WT mice were dead on day 2 in (D). (E) WT and Pirb−/− mice were i.v. infected with S. aureus (5 × 108 CFU per mouse). The following day, IL-6 and IL-1β in blood were measured by ELISA. *p < 0.05, **p < 0.01, log-rank test (A, B) or two-tailed Student t test (D, E). Similar results were obtained in at least three independent experiments.

Enhanced ERK1/2 and caspase-1 activation in Pirb−/− macrophages postinfection with live S. aureus

We next addressed intracellular signaling in BMDMs infected with live S. aureus. Consistent with in vivo results, BMDMs from Pirb−/− mice produced higher amounts of IL-6 and IL-1β in response to live S. aureus (Fig. 3A). Although ITIMs of PIR-B are constitutively phosphorylated in macrophages (34), infection with live S. aureus enhanced the phosphorylation (Fig. 3B). We next addressed MAPK and NF-κB activation in macrophages infected with live S. aureus. Although p38K and NF-κB activation were similar between Pirb−/− and WT macrophages, the phosphorylation level of ERK1/2 was markedly enhanced in Pirb−/− macrophages (Fig. 3C). We also analyzed pro–IL-1β production and caspase-1 activation, as the latter contributes to the processing of pro–IL-1β to mature IL-1β (35). Interestingly, Pirb−/− BMDMs showed not only enhanced pro–IL-1β (p35) production, but also elevated caspase-1 activation, as indicated by increased amounts of the cleaved p10 subunit of caspase-1 (Fig. 3D). Collectively, these results suggest that S. aureus targets PIR-B and negatively regulates ERK1/2 activation and inflammasome activation to dampen inflammatory cytokine secretion. Because it has been reported that inflammatory cytokine production depends on phagosome maturation (36), we examined phagosome/lysosome maturation in Pirb−/− BMDMs by confocal microscopy. However, we could not see the significant difference in colocalization of fluorescently labeled bacteria and lysosomes between WT and Pirb−/− BMDMs (data not shown), suggesting that PIR-B does not regulate phagosome maturation during S. aureus infection.

FIGURE 3.
FIGURE 3.

Pirb−/− macrophages show enhanced inflammatory responses to live S. aureus. (A) BMDMs from WT and Pirb−/− mice were cultured with S. aureus (moi 10) for the indicated periods of time. Production of IL-6 and IL-1β was measured by ELISA. (B) BMDMs were cultured with S. aureus as described in (A) for the indicated periods of time. PIR-B in total cell lysates was immunoprecipitated with 6C1 mAb. Phosphotyrosine and total protein levels of PIR-B were analyzed by immunoblot. Signal intensity of tyrosine-phosphorylated PIR-B proteins was normalized to the intensity of total PIR-B protein and was then compared with the control. *p < 0.05, **p < 0.01, two-tailed Student t test. (C and D) BMDMs were cultured with S. aureus as described in (A) for the indicated period of time. ERK1/2 and p38K phosphorylation, IκB-α degradation, and maturation of IL-1β and caspase-1 were analyzed by immunoblot. Similar results were obtained in at least three independent experiments.

Because PIR-B has been reported to bind MHC class I molecules (15), we next examined whether loss of MHC class I affects the interaction between PIR-B and S. aureus. We first verified that lack of cell surface expression of MHC class I H-2Kb or PIR-B did not affect each other’s expression on BMDMs (Fig. 4A). We further observed no substantial difference in S. aureus recognition (Fig. 4B) or cytokine production (Fig. 4C) in response to S. aureus between WT BMDMs and β2m-deficient BMDMs. These results indicate that MHC class I molecules do not affect the PIR-B–mediated manipulation of inflammatory cytokine release in macrophages infected with S. aureus.

FIGURE 4.
FIGURE 4.

MHC class I molecules do not affect the interaction between S. aureus and PIR-B. (A) WT, Pirb−/−, or β2m−/− BMDMs were stained with isotype control mAb (thin histogram) or mAb against the indicated cell surface protein (thick histogram) and analyzed by flow cytometry. (B) WT, Pirb−/−, or β2m−/− BMDMs were cultured with fluorescently labeled S. aureus (0.2, 1, or 5 moi) for 30 min at 4°C. Cells were then analyzed by flow cytometry. (C) WT, Pirb−/−, β2m−/− BMDMs were infected with S. aureus at 3 or 10 moi for 12 h at 37°C. Induction of IL-6 and IL-1β was measured by ELISA. Similar results were obtained in two (A, B) and three (C) independent experiments.

S. aureus binds PIR-B through the LTA and suppresses macrophage inflammatory responses to bacterial lipoprotein

To explore the molecular mechanism for the interaction between PIR-B and S. aureus, we screened various S. aureus mutant strains (listed in Fig. 5A, Table I) for their ability to bind PIR-B. The panel of mutants includes multiple strains with defects in genes responsible for the synthesis of specific cell-wall components. Each live mutant was labeled with TAMRA. After confirmation that fluorescent labeling did not affect bacterial survival by the CFU assay, and that the fluorescence intensity of each strain was largely equivalent by flow cytometry (data not shown), we analyzed the binding of bacteria to PIR-B. Expression of PIR-B enabled NIH3T3 cells to bind live WT S. aureus, and the binding was dramatically abrogated by a mutation of PIR-B in the surface loop of Ig-like domain 2 (Fig. 5B), which is consistent with our previous study using heat-killed bacteria (16). Notably, among the various mutant bacterial strains tested, only the LTA-deficient mutant (ΔltaS) failed to bind PIR-B (Fig. 5B). Staphylococcal LTA consists of ∼25 repeating units of poly (1-3)-glycerophosphate linked to a membrane lipid, and the ΔltaS mutation causes a loss in these extracellular repeating units (22). This negatively charged physical feature may be important for the interaction between S. aureus and PIR-B. Mutant bacterial strains with defects in WTA (ΔtagO), d-alanylation of both WTA and LTA (ΔdltA), glycolipids (ΔypfP), or lysylphosphatidylglycerol (ΔmprF), as well as the parental RN4220 strain, bound to PIR-B. A loss of expression of sle1 and atl, which code for amidase and an amidase-glucosamidase fusion protein involved in the degradation of peptidoglycan on the bacterial cell surface, respectively, did not affect the bacterial binding to PIR-B (Fig. 5B). The binding of PIR-B to mutant bacteria lacking all lipoprotein lipidation (Δlgt) or lacking a major lipoprotein, SitC (ΔsitC), was also comparable with that of the parental strain (Fig. 5B).

FIGURE 5.
FIGURE 5.

S. aureus binds PIR-B through LTA and suppresses macrophage inflammatory responses. (A) The strains of S. aureus used in this study and their phenotypes. (B) NIH3T3, PIR-B/NIH3T3, and PIR-B mutant/NIH3T3 cells were cultured with the indicated live TAMRA-labeled S. aureus strains (moi 50 each) for 30 min at 37°C. S. aureus recognition was analyzed by flow cytometry. Percentage of recognition was quantified, and data are represented as the mean + SD of triplicates. (C) NIH3T3, PIR-B/NIH3T3, and CD36/NIH3T3 cells were cultured with (thick histograms) or without (thin histograms) LTA (50 μg/ml) for 30 min at 4°C. LTA binding to cells was analyzed by flow cytometry using anti-LTA mAb. (D) NIH3T3 cells expressing PIR-B, SR-A, or CD36 were pretreated with the indicated dose of LTA, then cultured with TAMRA-labeled S. aureus as described in (B). The recognition (relative to recognition without LTA) was quantified by flow cytometry. Data are represented as the mean + SD of triplicates. (E) PIR-B phosphorylation in WT BMDMs cultured with the indicated S. aureus strain (moi 10 each) was analyzed as described in Fig. 3B. (F and G) BMDMs were cultured with the indicated S. aureus strain (moi 3 or 10 [F]; moi 10 [G]) for 12 h (F, G) or 24 h (G) at 37°C. Production of IL-6 and IL-1β was analyzed by ELISA (F). Maturation of IL-1β and caspase-1 were analyzed by immunoblot (G). Similar results were obtained in at least three independent experiments.

We next examined whether purified LTA binds to PIR-B. As shown in Fig. 5C, LTA bound to NIH3T3 cells expressing PIR-B, but the binding activity was weaker than that to CD36, an authentic LTA receptor (10). We further examined the inhibitory effect of purified LTA on the binding of S. aureus to PIR-B. A high dose of LTA was required for abrogating the binding of S. aureus to not only PIR-B, but also SR-A and CD36 (Fig. 5D). These results suggest that LTA, but not WTA, glycolipids, or lipoprotein lipidation, is required for the binding of live S. aureus to the Ig-like domain 2 of PIR-B.

We next addressed macrophage responses to the LTA-deficient mutant strain, ΔltaS. PIR-B phosphorylation was not enhanced in response to this mutant strain (Fig. 5E), which is consistent with the defect in PIR-B binding by ΔltaS (Fig. 5B). Notably, WT BMDMs secreted higher amounts of IL-6 and IL-1β when infected with ΔltaS versus the parental RN4220; IL-6 and IL-1β production in ΔltaS-infected WT BMDMs were equivalent to those observed in Pirb−/− BMDMs (Fig. 5F). To confirm that the inhibitory effect on WT BMDMs was ascribed to LTA, we expressed the ltaS gene in our ΔltaS mutant strain (ΔltaS/ltaS+) and found that reconstitution of ltaS expression suppressed cytokine production by WT BMDMs (Fig. 5F). Consistent with this, the ΔltaS/ltaS+ strain enhanced PIR-B phosphorylation in BMDMs (Fig. 5E), further indicating that LTA is required for S. aureus–PIR-B interaction. LTA deficiency did not affect cytokine production from Pirb−/− macrophages. Consistent with increased IL-1β secretion, the ΔltaS mutant induced comparable caspase-1 activation and IL-1β processing in WT and Pirb−/− BMDMs, as seen by bands of similar intensity for the cleaved caspase-1 p10 subunit and mature IL-1β (p17) (Fig. 5G). These results suggest that LTA is an essential cell-wall component of S. aureus that binds to PIR-B and consequently suppresses inflammatory responses in BMDMs.

LTA has been considered to be a ligand for TLR2; however, recent studies have questioned an inflammatory role for LTA from S. aureus, because a considerable amount of the activity in LTA preparations has been assigned to lipoprotein contamination, even in highly purified samples (10, 25, 37). We and others have recently reported that lipoprotein lipidation-deficient (Δlgt) S. aureus is unable to stimulate TLR2, indicating that lipoprotein is a major TLR2 ligand (25, 37). Consistent with these reports, Δlgt S. aureus failed to induce inflammatory cytokine production either from WT or Pirb−/− BMDMs (Fig. 6). Taken together, these results suggest that S. aureus targets PIR-B via LTA, which negatively regulates lipoprotein-mediated proinflammatory cytokine production.

FIGURE 6.
FIGURE 6.

PIR-B regulates lipoprotein-mediated inflammatory responses. BMDMs were cultured with the indicated S. aureus strain (moi 10) for 12 h at 37°C. Production of IL-6 and IL-1β was analyzed by ELISA. Similar results were obtained in three independent experiments.

Uncontrolled LTA-deficient S. aureus growth in both WT and Pirb−/− mice in vivo

We next compared the susceptibility of WT and Pirb−/− mice to ΔltaS infection. Although Pirb−/− mice were resistant to WT S. aureus infection (Fig. 2A–D), no significant difference was observed in susceptibility to ΔltaS infection (1 × 108 or 3 × 108 CFU) between WT and Pirb−/− mice (Fig. 7A, 7B). These data suggest that the interaction between bacterial LTA and host PIR-B affects mouse susceptibility to S. aureus infection. Although we hypothesized the ΔltaS mutant to be less pathogenic because of diminished ligation of the inhibitory PIR-B, WT mice were unexpectedly more susceptible to ΔltaS than ΔltaS/ltaS+ (Fig. 7C). Further, the ΔltaS mutant survived more than ΔltaS/ltaS+ in the blood of WT mice (Fig. 7D). To uncover the mechanism for this heightened virulence, we examined recognition of the ΔltaS mutant by splenic macrophages. WT splenic macrophages recognized this mutant poorly, at levels less than those observed for recognition of the ΔltaS/ltaS+ strain by Pirb−/− macrophages (Fig. 7E, 7F). This is probably due to the fact that S. aureus lacking LTA failed to be recognized by not only PIR-B, but also a wide variety of PRRs such as SR-A and MBL that accelerate the elimination of bacteria (10). Indeed, SR-A failed to recognize the ΔltaS mutant (Fig. 7G). The highly virulent phenotype of ΔltaS therefore appears to be caused by escape from host innate immune recognition in mice, a conclusion supported by studies in Drosophila (38). Collectively, these results suggest that S. aureus targets PIR-B through LTA to acquire virulence, whereas the host defense system also targets LTA by using a wide variety of PRRs, in addition to the inhibitory PIR-B, to bring about effective bacterial clearance and overcome infection (Fig. 7H).

FIGURE 7.
FIGURE 7.

LTA-deficient S. aureus escapes macrophage recognition. (A) Mice were infected with ΔltaS as follows: solid lines represent WT mice (blue; n = 7) or Pirb−/− mice (red; n = 6) with ΔltaS (1 × 108 CFU per mouse); broken lines represent WT mice (blue; n = 7) or Pirb−/− mice (red; n = 5) with ΔltaS (3 × 108 CFU per mouse). Survival was monitored for 15 d postinfection. (B) WT mice (n = 6) or Pirb−/− mice (n = 4) were i.v. infected with ΔltaS (1 × 108 CFU per mouse). Bacterial number in blood 1 d postinfection was determined. (C) WT mice were i.v. infected with ΔltaS/ltaS+ (blue line; n = 5) or ΔltaS (gray line; n = 8; 2 × 108 CFU each per mouse). Survival was monitored for 15 d postinfection. (D) WT mice (n = 5) were i.v. infected with ΔltaS/ltaS+ or ΔltaS (2 × 108 CFU each per mouse). Bacterial number in blood 1 d postinfection was determined. (E and F) WT and Pirb−/− mice (n = 3 per group) were i.v. injected with the indicated strains of TAMRA-labeled S. aureus (3 × 108 CFU per mouse). Recognition of S. aureus by F4/80+ CD11b+ splenic macrophages was analyzed 1 h later (E) and represented as mean + SD in (F). (G) Indicated NIH3T3 cells were cultured with TAMRA-labeled ΔltaS or ΔltaS/ltaS+, and recognition was analyzed as described in Fig. 5B. *p < 0.05, **p < 0.01, two-tailed Student t test. Similar results were obtained in three (A–F) or two (G) independent experiments. (H) Model of the host–bacteria interactions. S. aureus targets PIR-B via LTA to suppress lipoprotein/TLR-mediated inflammatory responses and survive in the host. PRRs other than PIR-B also target LTA for the bacterial clearance to overcome the infection.

Discussion

We demonstrate in this study that S. aureus exploits PIR-B, an inhibitory PRR, to dampen inflammatory responses and survive in the host. Our findings reinforce the current hypothesis that pathogens target paired inhibitory receptors to dampen immune responses against them (19, 20). We further identified LTA as an essential cell-wall component of S. aureus that binds PIR-B and, subsequently, modulates inflammatory responses. Furthermore, we showed that a lipoprotein lipidation-deficient (Δlgt) mutant failed to induce inflammatory cytokine release either from WT or Pirb−/− BMDMs. Collectively, these results indicate that S. aureus targets PIR-B through LTA to dampen bacterial lipoprotein-mediated inflammatory responses and thus increase virulence. Given that PIR-B does not bind to Listeria monocytogenes or Bacillus subtilis (16) even though their cell walls contain LTA, and that the affinity of purified LTA to PIR-B is low, we cannot rule out the possibility that PIR-B may require not only LTA but also simultaneous recognition of some other S. aureus components for binding.

Contrary to our hypothesis that the LTA-deficient mutant would be less pathogenic because of impaired stimulation of PIR-B, the LTA-deficient mutant exhibited a highly virulent phenotype. Given that LTA is the bacterial ligand for a wide variety of PRRs (10), the highly virulent phenotype of the ΔltaS mutant may be caused by escape from phagocytic clearance. Therefore, LTA is a key molecule in the host–microbe interaction where two conflicting immune reactions intersect.

Interestingly, Pirb−/− BMDMs showed enhanced caspase-1 activation, suggesting that PIR-B negatively regulates inflammasome activation in response to S. aureus infection. Notably, it has been reported that an ITAM receptor activates inflammasomes through Syk (39, 40). Although ITAM receptors capable of recognizing nonopsonized S. aureus remain to be identified, PIR-B may negatively regulate the signaling through such an activating receptor. Besides macrophages, monocytes and neutrophils, which play an important role for bacterial clearance in blood, express PIR-B on their cell surface (12, 13). Thus, PIR-B may also suppress these immune cell functions upon S. aureus bloodstream infections.

Is the inflammatory response beneficial for host defense against bacterial infection? This study using PIR-B–deficient mice showed that enhanced inflammation was effective for the clearance of WT S. aureus, but not for the ΔltaS mutant strain that escaped macrophage recognition. Therefore, as long as bacteria are normally recognized and phagocytosed by macrophages, enhanced inflammation could be beneficial for host defense, at least in the case of Gram-positive sepsis that causes relatively mild inflammation. Consistent with this notion, TLR2- and CD36-deficient mice develop less inflammation and are more susceptible to S. aureus infection than are WT counterparts (41, 42). Conversely, in Gram-negative infections that cause marked inflammation, these robust inflammatory responses must be regulated to prevent host damages. Indeed, Roger et al. (43) have reported that mice deficient for TLR4 or MyD88 are resistant to Gram-negative E. coli–induced septic shock. Although the inhibitory receptor CD200R is not a PRR, mice deficient for its ligand CD200 produce enhanced inflammatory cytokines in response to Gram-negative Neisseria meningitidis infection, and these mice succumb to infection (44). PIR-B–deficient mice also show enhanced inflammatory responses and are susceptible to Gram-negative Salmonella infection (45). Thus, the immune system must fine-tune the level of inflammation to achieve effective clearance of bacteria without causing host damage.

Interestingly, it has also been proposed that pathogens exert pressure that drives the evolution of paired receptors (19). Notably, although PIR-A has only a short cytoplasmic region, three ITIM-like motifs are preserved as relics in the 3′-untranslated region (Supplemental Fig. 2), suggesting that inhibitory PIR-B was the original receptor, and that multiple forms of PIR-A might have evolved from an ancestral PIR-B in an effort to try to buffer/control immune responses.

In this study, we have shown that S. aureus exploits PIR-B for virulence. PIR-B, which is not expressed in humans, has been proposed to be a human ortholog of ITIM-bearing Ig-like transcript (ILT)/leukocyte Ig-like receptor family members, based on similarities in structure, expression profiles, and genomic location (46). We have previously reported that the ectopic expression of ILT2 or ILT5 on NIH3T3 cells enables these cells to recognize S. aureus (16), and we further observed the expression of both ILT2 and ILT5 on human peripheral monocytes that efficiently recognize S. aureus (data not shown). However, it remains unknown whether these ILT receptors are involved in S. aureus recognition by monocytes. It also remains unknown whether another ITIM-bearing ILT such as ILT3, ILT4, and leukocyte Ig-like receptor 8 contribute to the recognition, and/or collaborate with each other in the efficient recognition of bacteria. Further human study using neutralizing mAbs or small interfering RNA will be required to address these issues. If S. aureus targets these ITIM-bearing receptors on human macrophages and monocytes for virulence, these inhibitory receptors could be novel therapeutic targets for sepsis.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank Chika Takahashi, Madoka Itabashi, and Misato Tsugita for technical assistance; Yoshinobu Nakanishi, Tatsuya Saitoh, and Yuki Katayama for helpful discussions; Toshio Kitamura for pMXs vectors; and Edward A. Miao for critical reading of the manuscript.

Footnotes

  • This work was supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (to M.N. and K. Ogasawara), Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan (H22-meneki-ippan-004 to K. Ogasawara; H22-meneki-ippan-005 to M.N.), the Mishima Kaiun Memorial Foundation (to M.N.), and a Grant-in-Aid (S1201013) from the Ministry of Education, Culture, Sports, Science and Technology–Supported Program for the Strategic Research Foundation at Private Universities (to H.Y. and K.H.).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article:

    BMDM
    bone marrow–derived macrophage
    ILT
    Ig-like transcript
    LB
    Luria–Bertani
    LTA
    lipoteichoic acid
    β2m
    β2-microglobulin
    MBL
    mannose-binding lectin
    moi
    multiplicity of infection
    PIR
    paired Ig-like receptor
    PRR
    pattern-recognition receptor
    SR-A
    class A scavenger receptor
    TAMRA
    5-(and-6)-carboxytetramethylrhodamine
    WT
    wild-type
    WTA
    wall teichoic acid.

  • Received July 13, 2012.
  • Accepted October 15, 2012.

References

  1. ↵
    1. Martin G. S.,
    2. D. M. Mannino,
    3. S. Eaton,
    4. M. Moss
    . 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546–1554.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Fournier B.,
    2. D. J. Philpott
    . 2005. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 18: 521–540.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Opal S. M.,
    2. J. Cohen
    . 1999. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit. Care Med. 27: 1608–1616.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Abe R.,
    2. S. Oda,
    3. T. Sadahiro,
    4. M. Nakamura,
    5. Y. Hirayama,
    6. Y. Tateishi,
    7. K. Shinozaki,
    8. H. Hirasawa
    . 2010. Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Crit. Care 14: R27.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Abraham E.,
    2. T. Evans
    . 2002. Corticosteroids and septic shock. JAMA 288: 886–887.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Lowy F. D.
    1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520–532.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Takeuchi O.,
    2. S. Akira
    . 2010. Pattern recognition receptors and inflammation. Cell 140: 805–820.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Muñoz-Planillo R.,
    2. L. Franchi,
    3. L. S. Miller,
    4. G. Núñez
    . 2009. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J. Immunol. 183: 3942–3948.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Shimada T.,
    2. B. G. Park,
    3. A. J. Wolf,
    4. C. Brikos,
    5. H. S. Goodridge,
    6. C. A. Becker,
    7. C. N. Reyes,
    8. E. A. Miao,
    9. A. Aderem,
    10. F. Götz,
    11. et al
    . 2010. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe 7: 38–49.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Weidenmaier C.,
    2. A. Peschel
    . 2008. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat. Rev. Microbiol. 6: 276–287.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Park K. H.,
    2. K. Kurokawa,
    3. L. Zheng,
    4. D. J. Jung,
    5. K. Tateishi,
    6. J. O. Jin,
    7. N. C. Ha,
    8. H. J. Kang,
    9. M. Matsushita,
    10. J. Y. Kwak,
    11. et al
    . 2010. Human serum mannose-binding lectin senses wall teichoic acid Glycopolymer of Staphylococcus aureus, which is restricted in infancy. J. Biol. Chem. 285: 27167–27175.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Foster T. J.
    2005. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3: 948–958.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Rooijakkers S. H.,
    2. K. P. van Kessel,
    3. J. A. van Strijp
    . 2005. Staphylococcal innate immune evasion. Trends Microbiol. 13: 596–601.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kubagawa H.,
    2. P. D. Burrows,
    3. M. D. Cooper
    . 1997. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc. Natl. Acad. Sci. USA 94: 5261–5266.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Takai T.
    2005. A novel recognition system for MHC class I molecules constituted by PIR. Adv. Immunol. 88: 161–192.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Nakayama M.,
    2. D. M. Underhill,
    3. T. W. Petersen,
    4. B. Li,
    5. T. Kitamura,
    6. T. Takai,
    7. A. Aderem
    . 2007. Paired Ig-like receptors bind to bacteria and shape TLR-mediated cytokine production. J. Immunol. 178: 4250–4259.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Slevogt H.,
    2. S. Zabel,
    3. B. Opitz,
    4. A. Hocke,
    5. J. Eitel,
    6. P. D. N’guessan,
    7. L. Lucka,
    8. K. Riesbeck,
    9. W. Zimmermann,
    10. J. Zweigner,
    11. et al
    . 2008. CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat. Immunol. 9: 1270–1278.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Carlin A. F.,
    2. Y. C. Chang,
    3. T. Areschoug,
    4. G. Lindahl,
    5. N. Hurtado-Ziola,
    6. C. C. King,
    7. A. Varki,
    8. V. Nizet
    . 2009. Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J. Exp. Med. 206: 1691–1699.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Barclay A. N.,
    2. D. Hatherley
    . 2008. The counterbalance theory for evolution and function of paired receptors. Immunity 29: 675–678.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hajishengallis G.,
    2. J. D. Lambris
    . 2011. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol. 11: 187–200.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ujike A.,
    2. K. Takeda,
    3. A. Nakamura,
    4. S. Ebihara,
    5. K. Akiyama,
    6. T. Takai
    . 2002. Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(−/−) mice. Nat. Immunol. 3: 542–548.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Oku Y.,
    2. K. Kurokawa,
    3. M. Matsuo,
    4. S. Yamada,
    5. B. L. Lee,
    6. K. Sekimizu
    . 2009. Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic acid in growth of Staphylococcus aureus cells. J. Bacteriol. 191: 141–151.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Bae T.,
    2. O. Schneewind
    . 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55: 58–63.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Novick R. P.,
    2. H. F. Ross,
    3. S. J. Projan,
    4. J. Kornblum,
    5. B. Kreiswirth,
    6. S. Moghazeh
    . 1993. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J. 12: 3967–3975.
    OpenUrlPubMed
  25. ↵
    1. Kurokawa K.,
    2. H. Lee,
    3. K. B. Roh,
    4. M. Asanuma,
    5. Y. S. Kim,
    6. H. Nakayama,
    7. A. Shiratsuchi,
    8. Y. Choi,
    9. O. Takeuchi,
    10. H. J. Kang,
    11. et al
    . 2009. The triacylated ATP binding cluster transporter substrate-binding lipoprotein of Staphylococcus aureus functions as a native ligand for Toll-like receptor 2. J. Biol. Chem. 284: 8406–8411.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kaito C.,
    2. K. Sekimizu
    . 2007. Colony spreading in Staphylococcus aureus. J. Bacteriol. 189: 2553–2557.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Ichihashi N.,
    2. K. Kurokawa,
    3. M. Matsuo,
    4. C. Kaito,
    5. K. Sekimizu
    . 2003. Inhibitory effects of basic or neutral phospholipid on acidic phospholipid-mediated dissociation of adenine nucleotide bound to DnaA protein, the initiator of chromosomal DNA replication. J. Biol. Chem. 278: 28778–28786.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Kajimura J.,
    2. T. Fujiwara,
    3. S. Yamada,
    4. Y. Suzawa,
    5. T. Nishida,
    6. Y. Oyamada,
    7. I. Hayashi,
    8. J. Yamagishi,
    9. H. Komatsuzawa,
    10. M. Sugai
    . 2005. Identification and molecular characterization of an N-acetylmuramyl-L-alanine amidase Sle1 involved in cell separation of Staphylococcus aureus. Mol. Microbiol. 58: 1087–1101.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Takahashi J.,
    2. H. Komatsuzawa,
    3. S. Yamada,
    4. T. Nishida,
    5. H. Labischinski,
    6. T. Fujiwara,
    7. M. Ohara,
    8. J. Yamagishi,
    9. M. Sugai
    . 2002. Molecular characterization of an atl null mutant of Staphylococcus aureus. Microbiol. Immunol. 46: 601–612.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Nakayama M.,
    2. H. Akiba,
    3. K. Takeda,
    4. Y. Kojima,
    5. M. Hashiguchi,
    6. M. Azuma,
    7. H. Yagita,
    8. K. Okumura
    . 2009. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113: 3821–3830.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Kubagawa H.,
    2. C. C. Chen,
    3. L. H. Ho,
    4. T. S. Shimada,
    5. L. Gartland,
    6. C. Mashburn,
    7. T. Uehara,
    8. J. V. Ravetch,
    9. M. D. Cooper
    . 1999. Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. J. Exp. Med. 189: 309–318.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Rämet M.,
    2. A. Pearson,
    3. P. Manfruelli,
    4. X. Li,
    5. H. Koziel,
    6. V. Göbel,
    7. E. Chung,
    8. M. Krieger,
    9. R. A. Ezekowitz
    . 2001. Drosophila scavenger receptor CI is a pattern recognition receptor for bacteria. Immunity 15: 1027–1038.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Nakayama M.,
    2. K. Takeda,
    3. M. Kawano,
    4. T. Takai,
    5. N. Ishii,
    6. K. Ogasawara
    . 2011. Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4+ T cells. Proc. Natl. Acad. Sci. USA 108: 18360–18365.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Ho L. H.,
    2. T. Uehara,
    3. C. C. Chen,
    4. H. Kubagawa,
    5. M. D. Cooper
    . 1999. Constitutive tyrosine phosphorylation of the inhibitory paired Ig-like receptor PIR-B. Proc. Natl. Acad. Sci. USA 96: 15086–15090.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Schroder K.,
    2. J. Tschopp
    . 2010. The inflammasomes. Cell 140: 821–832.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Ip W. K.,
    2. A. Sokolovska,
    3. G. M. Charriere,
    4. L. Boyer,
    5. S. Dejardin,
    6. M. P. Cappillino,
    7. L. M. Yantosca,
    8. K. Takahashi,
    9. K. J. Moore,
    10. A. Lacy-Hulbert,
    11. L. M. Stuart
    . 2010. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus. J. Immunol. 184: 7071–7081.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Hashimoto M.,
    2. K. Tawaratsumida,
    3. H. Kariya,
    4. A. Kiyohara,
    5. Y. Suda,
    6. F. Krikae,
    7. T. Kirikae,
    8. F. Götz
    . 2006. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177: 3162–3169.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Hashimoto Y.,
    2. Y. Tabuchi,
    3. K. Sakurai,
    4. M. Kutsuna,
    5. K. Kurokawa,
    6. T. Awasaki,
    7. K. Sekimizu,
    8. Y. Nakanishi,
    9. A. Shiratsuchi
    . 2009. Identification of lipoteichoic acid as a ligand for draper in the phagocytosis of Staphylococcus aureus by Drosophila hemocytes. J. Immunol. 183: 7451–7460.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Gross O.,
    2. H. Poeck,
    3. M. Bscheider,
    4. C. Dostert,
    5. N. Hannesschläger,
    6. S. Endres,
    7. G. Hartmann,
    8. A. Tardivel,
    9. E. Schweighoffer,
    10. V. Tybulewicz,
    11. et al
    . 2009. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459: 433–436.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Gringhuis S. I.,
    2. T. M. Kaptein,
    3. B. A. Wevers,
    4. B. Theelen,
    5. M. van der Vlist,
    6. T. Boekhout,
    7. T. B. Geijtenbeek
    . 2012. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat. Immunol. 13: 246–254.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Takeuchi O.,
    2. K. Hoshino,
    3. S. Akira
    . 2000. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 165: 5392–5396.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Hoebe K.,
    2. P. Georgel,
    3. S. Rutschmann,
    4. X. Du,
    5. S. Mudd,
    6. K. Crozat,
    7. S. Sovath,
    8. L. Shamel,
    9. T. Hartung,
    10. U. Zähringer,
    11. B. Beutler
    . 2005. CD36 is a sensor of diacylglycerides. Nature 433: 523–527.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Roger T.,
    2. C. Froidevaux,
    3. D. Le Roy,
    4. M. K. Reymond,
    5. A. L. Chanson,
    6. D. Mauri,
    7. K. Burns,
    8. B. M. Riederer,
    9. S. Akira,
    10. T. Calandra
    . 2009. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc. Natl. Acad. Sci. USA 106: 2348–2352.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Mukhopadhyay S.,
    2. A. Plüddemann,
    3. J. C. Hoe,
    4. K. J. Williams,
    5. A. Varin,
    6. K. Makepeace,
    7. M. L. Aknin,
    8. D. M. Bowdish,
    9. S. T. Smale,
    10. A. N. Barclay,
    11. S. Gordon
    . 2010. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe 8: 236–247.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Torii I.,
    2. S. Oka,
    3. M. Hotomi,
    4. W. H. Benjamin Jr..,
    5. T. Takai,
    6. J. F. Kearney,
    7. D. E. Briles,
    8. H. Kubagawa
    . 2008. PIR-B-deficient mice are susceptible to Salmonella infection. J. Immunol. 181: 4229–4239.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Takai T.,
    2. M. Ono
    . 2001. Activating and inhibitory nature of the murine paired immunoglobulin-like receptor family. Immunol. Rev. 181: 215–222.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section